Site growth

Opening a second research site location: when it makes sense

By TrialNotice · Updated
Site director holding blueprints in an empty newly leased office space at sunset
Short answerA second location makes sense when your first site is consistently at capacity, sponsors would place studies there, you have an investigator ready to lead it, and the new market has patients you cannot reach today. Buyers value multi site operators more, but a second location doubles overhead before it doubles revenue, so test demand and build the patient pipeline before signing a lease.

When does a second location make sense?

  • Your first site turns down studies for lack of capacity, not lack of fit.
  • Sponsors you work with have asked about the new area.
  • An investigator is ready to lead the new site.
  • The new market has patients and specialists you cannot reach from your current location.

Why does location matter so much?

Patients and physicians care about distance. In one physician survey, proximity to a research center raised the odds of likely referral about fourfold (PubMed). Buyers also value sites in diverse, dense markets because they enroll faster (Objective IBV).

How do you evaluate a market?

  1. Trial demand: count recruiting studies in your therapeutic areas near the new location on ClinicalTrials.gov (ClinicalTrials.gov).
  2. Competition: how many other sites already run those studies.
  3. Specialists: count the physicians who manage your target conditions there, using the CMS NPPES registry. They are the referral base.
  4. Talent: can you hire coordinators there?

What does it cost before it pays?

Lease, buildout, equipment, staff, and the startup work for the first studies, with revenue arriving months later. Sites at SCRS recommended at least three months of working capital and warned that big new studies cause cash crunches (Bourne Partners).

Is there a lighter alternative?

Yes: a satellite inside an existing practice. Physician practices are the fastest site type to first patient in (Applied Clinical Trials), and partnering with one gives you space and patients without a new lease.

What should be ready before opening day?

A patient pipeline. Brief the specialists around the new location before the first study arrives, so the new site enrolls from its first activation instead of starting from zero. See standardizing recruitment across locations.

Get your study in front of the right local physicians

TrialNotice builds a physician referral pipeline around one active study. We identify relevant local physicians within driving distance of your site, send study aligned direct mail, follow up by email and LinkedIn, track engagement with recipient level QR codes, and route warm responses into your site team's workflow.

Talk to TrialNotice

Sources

  1. Objective Investment Banking and Valuation, "Valuation of Clinical Research Sites: What Buyers Look For"
  2. Bourne Partners, "Update on the Fundamentals of Clinical Trial Sites" (SCRS Global Site Solutions Summit takeaways, October 2025)
  3. ClinicalTrials.gov API, recruiting industry funded studies with US locations, queried October 4, 2026
  4. Applied Clinical Trials, "New Benchmarks for Trial Initiation Activities" (Tufts CSDD)
  5. "Predictors of physician referral for patient recruitment to Alzheimer disease clinical trials," Alzheimer Disease and Associated Disorders, PubMed

Keep reading

Two clinical research site staff members reviewing a growth plan together in a bright office
Site growth

How to grow a clinical research site: a practical playbook

Research sites grow by building a record sponsors can verify: enrollment, startup speed, and screen failure. Here is what the data says about site growth, why sponsors reuse sites, and a six step playbook.

 Research site director presenting enrollment results to sponsor representatives across a conference table
Site growth

How research sites get more studies from sponsors and CROs

Sponsors award more studies to sites that enroll reliably, start fast, and forecast honestly. Here is how sponsors choose, why new sites face a slower path, and what a site can do to win repeat work.

 Sponsor clinical operations team reviewing site maps and performance charts on a large screen
Site growth

How sponsors and CROs select clinical trial sites

Sponsors shortlist sites with historical data and epidemiology, send feasibility questionnaires, then choose on patient access, past enrollment, and startup speed. Here is the process, how it evolved, and what it means for sites.